Publications by authors named "Sabrina Eymard-Duvernay"

Objectives: The diagnostic gaps for childhood tuberculosis (TB) remain considerable in settings with high TB incidence and resource constraints. We established and evaluated the performance of a scoring system based on a combination of serological tests and T-cell cytokine release assays, chosen for their ability to detect immune responses indicative of TB, in a context of high prevalence of pediatric HIV infection.

Methods: We enrolled 628 consecutive children aged ≤15 years, admitted for TB suspicion.

View Article and Find Full Text PDF

Background: Mother-to-child transmission of HIV during breastfeeding remains a challenge in low- and middle-income countries (LMIC). A prevention package was initiated during the highly attended 2nd visit of the Expanded Program of Immunisation (EPI-2) to identify the undiagnosed infants living with HIV and reduce the postnatal transmission of infant exposed to HIV.

Methods: PREVENIR-PEV is a non-randomized phase II clinical trial conducted at two health centres in Bobo Dioulasso (Burkina Faso).

View Article and Find Full Text PDF

Context: At least 40% of cancers are linked to environmental or behavioral factors, and dietary behavior appears to be a major lever. Epidaure Market is a prevention initiative developed using a method for co-constructing health promotion initiatives and prevention programs that stratifies evidence from the scientific literature and combines it with experiential knowledge (DEVA, TPB, BCT). It promotes a sustainable diet (i.

View Article and Find Full Text PDF
Article Synopsis
  • Integrase strand transfer inhibitors (INSTIs) are now the recommended first-line treatment for HIV in low- and middle-income countries due to rising resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs).
  • A study analyzed samples from West Africa and Southeast Asia to assess the prevalence of pretreatment drug resistance (PDR) to INSTIs, finding a low frequency of 1.1% while overall PDR to any drug class was significantly higher at 17.9%.
  • The findings advocate for the use of INSTIs in these regions yet highlight the urgent need to prevent further drug resistance to ensure effective treatment outcomes.
View Article and Find Full Text PDF
Article Synopsis
  • - The study validated the Minimum Dietary Diversity for Women of Reproductive Age (MDD-W) as a measure of micronutrient adequacy for pregnant women in low- and middle-income countries (LMICs), addressing a gap in research for this specific group.
  • - Researchers analyzed data from 4 LMICs (Bangladesh, Burkina Faso, India, and Nepal) with 4,909 participants to evaluate the relationship between food group diversity (measured by Women's Dietary Diversity Score - WDDS-10) and micronutrient adequacy (MPA).
  • - Results indicated that a threshold of 5 or more food groups significantly predicted adequate micronutrient intake among pregnant women, showing strong sensitivity and specificity, suggesting
View Article and Find Full Text PDF

Urban-poor households are disproportionately food insecure. The Status and Determinants of Food Insecurity and Undernutrition in Poor Urban Settings (SDFU) cross-sectional surveys were conducted in 2020-2021 to assess the impacts of COVID-19 on food security and diet quality among urban poor women of reproductive age (WRA) and children under 5 (CU5) in Jakarta, Quezon City, and Yangon. Data, collected on food insecurity and child and maternal diet quality using Computer Assisted Telephone Interviewing (CATI), were compared with prepandemic surveys.

View Article and Find Full Text PDF

Multiple forms of malnutrition coexist in Peru, especially in peri-urban areas and poor households. We investigated the magnitude of, and the contribution of, dietary and socio-demographic factors to the double burden of malnutrition (DBM) at maternal (i.e.

View Article and Find Full Text PDF

Objective: To evaluate the performance of the cascade of activities for prevention of mother-to-child transmission (PMTCT) of human immunodeficiency virus (HIV) at the second immunization visit in Burkina Faso.

Methods: In a cross-sectional study, we recruited mothers attending the second immunization visit for their infant in 20 health centres of Bobo-Dioulasso city, Burkina Faso over 12 months (2019-2020). We administered a short questionnaire to 14 176 mothers and performed HIV serological tests on mothers who had not been tested in the last 3 months.

View Article and Find Full Text PDF

The COVID-19 pandemic may impact diet and nutrition through increased household food insecurity, lack of access to health services, and poorer quality diets. The primary aim of this study is to assess the impact of the pandemic on dietary outcomes of mothers and their infants and young children (IYC) in low-income urban areas of Peru. We conducted a panel study, with one survey prepandemic (n = 244) and one survey 9 months after the onset of COVID-19 (n = 254).

View Article and Find Full Text PDF

Introduction: G1 and G2 alleles have been associated with kidney-related outcomes in people living with HIV (PLHIV) of Black African origin. No APOL1-related kidney risk data have yet been reported in PLHIV in West Africa, where high allele frequencies have been observed.

Methods: We collected clinical data from PLHIV followed in Burkina Faso ( = 413) and in the ANRS-12169/2LADY trial (Cameroon, Senegal, Burkina Faso,  = 369).

View Article and Find Full Text PDF

Telomere shortening can be enhanced upon human immunodeficiency virus (HIV) infection and by antiretroviral (ARV) exposures. The aim of this study was to evaluate the acute and long-term effect on telomere shortening of two ARV prophylaxes, lopinavir/ritonavir (LPV/r) and lamivudine (3TC), administered to children who are HIV-exposed uninfected (CHEU) to prevent HIV acquisition through breastfeeding during the first year of life, and to investigate the relationship between telomere shortening and health outcomes at six years of age. We included 198 CHEU and measured telomere length at seven days of life, at week-50 and at six years (year-6) using quantitative polymerase chain reaction.

View Article and Find Full Text PDF

Post-natal HIV infection through breastfeeding remains a challenge in many low and middle-income countries, particularly due to non-availability of alternative infant feeding options and the suboptimal Prevention of Mother to Child Transmission of HIV-1 (PMTCT) cascade implementation and monitoring. The PROMISE-EPI study aims to address the latter by identifying HIV infected mothers during an almost never-missed visit for their infant, the second extended program on immunization visit at 6-8 weeks of age (EPI-2). The study is divided into 3 components inclusive of an open-label randomized controlled trial aiming to assess the efficacy of a responsive preventive intervention compared to routine intervention based on the national PMTCT guidelines for HIV-1 uninfected exposed breastfeeding infants.

View Article and Find Full Text PDF

Background: There are major gaps in the management of pediatric tuberculosis (TB) contact investigation for rapid identification of active tuberculosis and initiation of preventive therapy. This study aims to evaluate the impact of a community-based intervention as compared to facility-based model for the management of children in contact with bacteriologically confirmed pulmonary TB adults in low-resource high-burden settings.

Methods/design: This multicenter parallel open-label cluster randomized controlled trial is composed of three phases: I, baseline phase in which retrospective data are collected, quality of data recording in facility registers is checked, and expected acceptability and feasibility of the intervention is assessed; II, intervention phase with enrolment of index cases and contact cases in either facility- or community-based models; and III, explanatory phase including endpoint data analysis, cost-effectiveness analysis, and post-intervention acceptability assessment by healthcare providers and beneficiaries.

View Article and Find Full Text PDF
Article Synopsis
  • The ANRS12286/MOBIDIP trial found that a dual therapy using a boosted protease inhibitor (bPI) and lamivudine was more effective than bPI alone for patients with the M184V mutation.
  • Researchers analyzed M184V/I variants before treatment switches and during virological failure (VF) using ultra-deep sequencing on samples from 265 patients.
  • The study revealed that while a significant number of participants had M184V mutations, the effectiveness of the lamivudine-based dual therapy remained strong, indicating that the drug's residual activity largely contributed to treatment success despite the presence of these mutations.
View Article and Find Full Text PDF

Infant antiretroviral (ARV) prophylaxis given to children who are human immunodeficiency virus (HIV)-exposed but uninfected (CHEU) to prevent HIV transmission through breastfeeding previously proved its efficacy in the fight against the pediatric epidemic. However, few studies have investigated the short- and long-term safety of prophylactic regimens. We previously reported a decrease of mitochondrial DNA (mtDNA) content among CHEU who received one year of lamivudine (3TC) or lopinavir-boosted ritonavir (LPV/r) as infant prophylaxis.

View Article and Find Full Text PDF

Introduction: We assessed family physicians' (FP) willingness to integrate PrEP into their clinical practice in Montpellier and its surroundings.

Method: We aimed to randomly assess 92 FPs.

Results: Ninety-six FPs were interviewed from May to December 2018: 78% (95% CI [69; 86]) were willing to integrate PrEP, 65% to be trained, and 52% to be the first providers.

View Article and Find Full Text PDF

Background: Hepatitis B is a major concern in Africa, especially in HIV-infected patients. Unfortunately, access to hepatitis B virus (HBV) testing and adequate treatment remains a challenge in the continent. We investigated HBV testing, treatment, and virologic suppression in HIV-infected patients followed up as part of Cameroon's national antiretroviral programme.

View Article and Find Full Text PDF

Background: We assessed prevalence of multimorbidity (MM) according to year of human immunodeficiency virus (HIV) diagnosis in elderly people living with HIV (PLWH).

Methods: This was a cross-sectional study of MM in PLWH aged ≥70 years from the Dat'AIDS French multicenter cohort. MM was defined as at least 3 coexistent morbidities of high blood pressure, diabetes mellitus, osteoporosis, non-AIDS cancer, chronic renal failure, cardiovascular and cerebrovascular disease, obesity, undernutrition, or hypercholesterolemia.

View Article and Find Full Text PDF

Background: There are limited data on the comparative prevalence of neurocognitive impairment (NCI) in aging people living with human immunodeficiency virus (PLHIV) and people not living with HIV.

Methods: This was a cross-sectional study of PLHIV randomly matched by age (±4 years), gender, and education with 5 HIV-uninfected individuals from the CONSTANCES cohort. PLHIV were fluent in French and sequentially included during routine outpatient visits if aged 55-70 years, with HIV viral load <50 copies/mL, and lymphocyte T-CD4 level ≥200 cells/µL in the past 24 and 12 months, respectively.

View Article and Find Full Text PDF

Background: Perinatal treatment with lopinavir boosted by ritonavir (LPV/r) is associated with steroidogenic abnormalities. Long-term effects in infants have not been studied.

Methods: Adrenal-hormone profiles were compared at weeks 6 and 26 between human immunodeficiency virus (HIV)-1-exposed but uninfected infants randomly assigned at 7 days of life to prophylaxis with LPV/r or lamivudine (3TC) to prevent transmission during breastfeeding.

View Article and Find Full Text PDF

Background: An efavirenz-based regimen (with a 600-mg dose of efavirenz, known as EFV600) was the World Health Organization preferred first-line treatment for human immunodeficiency virus type 1 (HIV-1) infection until June 2018. Given concerns about side effects, dolutegravir-based and low-dose efavirenz-based combinations have been considered as first-line treatments for HIV-1 in resource-limited settings.

Methods: We conducted an open-label, multicenter, randomized, phase 3 noninferiority trial in Cameroon.

View Article and Find Full Text PDF

Background: Population-based studies to estimate viral load (VL) suppression and rate of acquired HIV drug resistance (ADR) are essential in sub-Saharan Africa. We conducted the first nationally representative study estimating VL suppression and ADR in Cameroon.

Methods: Eligible participants were patients on antiretroviral therapy (ART) for 12 to 24 months (ART 12-24) or 48 to 60 months (ART 48-60).

View Article and Find Full Text PDF
Article Synopsis
  • The WHO now recommends immediate treatment for HIV-positive individuals in developing countries, but a high frequency of pretreatment HIV drug resistance (PDR) poses risks to ART effectiveness.* -
  • The study analyzed 1153 adult ART initiators in seven countries, finding an overall PDR frequency of 15.9%, with notable variations across countries: from 9.6% in Burkina Faso to 24.6% in Togo.* -
  • Given that PDR exceeded 10% in most countries, the authors advocate for national surveys to assess the situation better and recommend transitioning to more effective drug classes to combat resistance.*
View Article and Find Full Text PDF
Article Synopsis
  • A study conducted in Cameroon found that about 10% of new HIV patients starting antiretroviral therapy (ART) have pretreatment HIV drug resistance (PDR), which can lead to treatment failure and higher mortality risks.
  • The research involved 379 participants from urban and rural clinics, with a higher prevalence of PDR observed in urban settings (14.2%) compared to rural ones (4.3%).
  • The findings highlight the need for more effective treatments with a higher resistance barrier, especially due to the concerns around non-nucleoside reverse transcriptase inhibitors (NNRTIs) that showed significant levels of resistance.
View Article and Find Full Text PDF